Filing Details
- Accession Number:
- 0001209191-18-017705
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-03-07 16:16:19
- Reporting Period:
- 2018-03-05
- Accepted Time:
- 2018-03-07 16:16:19
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
827871 | Eagle Pharmaceuticals Inc. | EGRX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1261026 | A Sander Flaum | C/O Eagle Pharmaceuticals, Inc. 50 Tice Blvd., Suite 315 Woodcliff Lake NJ 07677 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-03-05 | 2,340 | $0.90 | 13,714 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-03-06 | 2,340 | $53.94 | 11,374 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2018-03-05 | 2,340 | $0.00 | 2,340 | $0.90 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2018-03-06 | No | 4 | M | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.79 to $54.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- The option is fully vested and immediately exercisable.